Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antig...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Satta, Alessandro, Mezzanzanica, Delia, Caroli, Francesco, Frigerio, Barbara, Di Nicola, Massimo, Kontermann, Roland E., Iacovelli, Federico, Desideri, Alessandro, Anichini, Andrea, Canevari, Silvana, Gianni, Alessandro Massimo, Figini, Mariangela
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204841/
https://ncbi.nlm.nih.gov/pubmed/29993310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1494105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars